Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy

Journal of Viral Hepatitis

Volumn 13, Issue 11, 2006, Pages 734-741

  Potthoff, A ^a   Tillmann, H L ^a,b   Bara, C ^a   Deterding, K ^a   Pethig, K ^a,c   Meyer, S ^a   Haverich, A ^a   Boker K H W ^a   Manns, M P ^a   Wedemeyer, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Antiviral therapy; Heart transplantation; Hepatitis B; Survival

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN A; FAMCICLOVIR; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TENOFOVIR;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CARDIAC GRAFT REJECTION; CAUSE OF DEATH; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEART TRANSPLANTATION; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PILOT STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL TIME;

2-AMINOPURINE; ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEART TRANSPLANTATION; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LAMIVUDINE; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 33750053844     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00748.x     Document Type: Article

References (32)

1. Fagiuoli S, Minniti F, Pevere S et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant 2001; 20(7): 718.
2. Lucey MR, Graham DM, Martin P et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33(10): 1390.
3. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329(25): 1842.
4. Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337(8745): 813.
5. Crippin J, Foster B, Carlen S, Borcich A, Bodenheimer H, Jr. Retransplantation in hepatitis B - a multicenter experience. Transplantation 1994; 57(6): 823.
6. Huang MA, Lok AS. Natural history of hepatitis B and outcomes after liver transplantation. Clin Liver Dis 2003; 7(3): 521.
7. Fornairon S, Pol S, Legendre C et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62(2): 297.
8. Ridruejo E, Brunet Mdel R, Cusumano A et al. HBsAg as predictor of outcome in renal transplant patients. Medicina (B Aires) 2004; 64(5): 429.
9. Lunel F, Cadranel JF, Rosenheim M et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000; 119(4): 1064.
10. Wedemeyer H, Pethig K, Wagner D et al. Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 1998; 66(10): 1347.
11. Wedemeyer H, Pethig K, Manns MP, Boker KH. Hepatitis B infection in heart transplant patients. Gastroenterology 2001; 120(5): 1311.
12. Drescher J, Wagner D, Haverich A et al. Nosocomial hepatitis B virus infections in cardiac transplant recipients transmitted during transvenous endomyocardial biopsy. J Hosp Infect 1994; 26(2): 81.
13. de Man RA, M Balle AH, Jonkman FA et al. Patient to patient hepatitis B transmission during heart biopsy procedures. A report of the European Working Party on Viral Hepatitis in Heart Transplant Recipients. J Hosp Infect 1996; 34(1): 71.
14. Osterhaus AD, Vos MC, Balk AH et al. Transmission of hepatitis B virus among heart transplant recipients during endomyocardial biopsy procedures. J Heart Lung Transplant 1998; 17(2): 158.
15. Kruger M, Tillmann HL, Trautwein C et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 1996; 2(4): 253.
16. Tillmann HL, Trautwein C, Bock T et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30(1): 244.
17. Manns MP, Neuhaus P, Atkinson GF et al. Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study. Transpl Infect Dis 2001; 3(1): 16.
18. Wedemeyer H, Boker KH, Pethig K et al. Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. Transplantation 1999; 68(10): 1503.
19. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351(15): 1521.
20. Perrillo RP. Antiviral therapy to prevent and treat hepatitis B virus infection in hepatic allografts. Clin Transplant 2000; 14(Suppl. 2): 25.
21. Lapinski TW, Flisiak R, Jaroszewicz J, Michalewicz M, Kowalczuk O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol 2005; 11(3): 400.
22. Kamar N, Sandres-Saune K, Ribes D et al. Effects of long-term lamivudine therapy in renal-transplant patients. J Clin Virol 2004; 31(4): 298.
23. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77(6): 859.
24. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38(6): 1419.
25. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996; 40(6): 1514.
26. Tillmann H, Trautwein C, Walker D et al. Clinical relevance of mutations in the precore genome of the hepatitis B virus. Gut 1995; 37(4): 568.
27. Kliem V, Brunkhorst R, Frei U. [Kidney transplantation in patients with diseases of the gastrointestinal tract and the liver]. Dtsch Med Wochenschr 1995; 120(48): 1673.
28. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120(7): 1828.
29. van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40(6): 1421.
30. Shaw T, Bowden S, Locarnini S. Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints. Gastroenterology 2002; 123(6): 2135.
31. Westland CE, Yang H, Delaney WE et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12(1): 67.
32. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126(1): 81.